IGC - India Globalization Capital stock soars 37% on Alzheimer's drug trial update

India Globalization Capital (IGC) jumps 37.2% premarket after completing Cohort 3 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol ((THC))-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease ((AD)).IGC received FDA approval to proceed with the Phase 1 trial of IGC-AD1 in AD on July 30, 2020. Cohort 3 is the final cohort in IGC’s Alzheimer’s Phase 1 trial.The Data and Safety Monitoring Committee will review the data from Cohort 3, and IGC will report its findings from all three Cohorts to the FDA.The Cohort 3 administers three doses of IGC-AD1 per day. To IGC’s knowledge, this is the first human clinical trial using low doses of natural THC, a psychoactive member of the cannabinoid class of natural products produced by the Cannabis sativa plant, on Alzheimer’s patients.Earlier this month, the company completed Cohort 2 of its Phase 1 IGC-AD1 trial in Alzheimer’s disease.

For further details see:

India Globalization Capital stock soars 37% on Alzheimer’s drug trial update